Literature DB >> 16527742

APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.

Hui Chen1, Caroline E Lilley, Qin Yu, Darwin V Lee, Jody Chou, Iñigo Narvaiza, Nathaniel R Landau, Matthew D Weitzman.   

Abstract

APOBEC3 proteins constitute a family of cytidine deaminases that provide intracellular resistance to retrovirus replication and transposition of endogenous retroelements. One family member, APOBEC3A (hA3A), is an orphan, without any known antiviral activity. We show that hA3A is catalytically active and that it, but none of the other family members, potently inhibits replication of the parvovirus adeno-associated virus (AAV). hA3A was also a potent inhibitor of the endogenous LTR retroelements, MusD, IAP, and the non-LTR retroelement, LINE-1. Its function was dependent on the conserved amino acids of the hA3A active site, consistent with a role for cytidine deamination, although mutations in retroelement sequences were not found. These findings demonstrate the potent activity of hA3A, an APOBEC3 family member with no previously identified function. They also highlight the functional differences between APOBEC3 proteins. The APOBEC3 family members have distinct functions and may have evolved to resist various classes of genetic elements.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16527742     DOI: 10.1016/j.cub.2006.01.031

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  237 in total

1.  Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo.

Authors:  Rodolphe Suspène; Marie-Ming Aynaud; Stefanie Koch; David Pasdeloup; Marc Labetoulle; Barbara Gaertner; Jean-Pierre Vartanian; Andreas Meyerhans; Simon Wain-Hobson
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Large-scale DNA editing of retrotransposons accelerates mammalian genome evolution.

Authors:  Shai Carmi; George M Church; Erez Y Levanon
Journal:  Nat Commun       Date:  2011-11-01       Impact factor: 14.919

3.  APOBEC3 proteins and genomic stability: the high cost of a good defense.

Authors:  Iñigo Narvaiza; Sébastien Landry; Matthew D Weitzman
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

4.  The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.

Authors:  Marcel Ooms; Susan Majdak; Christopher W Seibert; Ariana Harari; Viviana Simon
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

5.  APOBEC3A possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer.

Authors:  Shan Chen; Xiao Li; Junpu Qin; Yuan Chen; Longyang Liu; Dongqing Zhang; Minyi Wang; Maocai Wang; Dikai Zhang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

6.  LINE-1 activity as molecular basis for genomic instability associated with light exposure at night.

Authors:  Victoria P Belancio
Journal:  Mob Genet Elements       Date:  2015-04-07

Review 7.  Post-transcriptional regulation of LINE-1 retrotransposition by AID/APOBEC and ADAR deaminases.

Authors:  Elisa Orecchini; Loredana Frassinelli; Silvia Galardi; Silvia Anna Ciafrè; Alessandro Michienzi
Journal:  Chromosome Res       Date:  2018-02-02       Impact factor: 5.239

8.  Genetically regulated epigenetic transcriptional activation of retrotransposon insertion confers mouse dactylaplasia phenotype.

Authors:  Hiroki Kano; Hiroki Kurahashi; Tatsushi Toda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-05       Impact factor: 11.205

9.  Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.

Authors:  Hal P Bogerd; Bryan R Cullen
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

10.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.